{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Peng C"],"funding":["NIA NIH HHS","NCI NIH HHS"],"pagination":["62"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12216965"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type."],"journal":["NPJ breast cancer"],"pubmed_title":["Regular aspirin use, breast tumor characteristics and long-term breast cancer survival."],"pmcid":["PMC12216965"],"funding_grant_id":["R01 CA050385","R01 CA049449","P01 CA087969","P01 CA87969","T32 CA009001","R01 CA166666","U01 CA176726","R01 CA067262","K01AG080030","U19 CA148065","R01 CA50385","K01 AG080030","UM1 CA186107"],"pubmed_authors":["Willett WC","Le PA","Holmes MD","Rosner BA","Schedin PJ","Stampfer MJ","Brantley KD","Chen WY","Peng C","Wang T","Heather Eliassen A","J Heng Y","Tamimi RM"],"additional_accession":[]},"is_claimable":false,"name":"Regular aspirin use, breast tumor characteristics and long-term breast cancer survival.","description":"Epidemiologic data, supported by experiments, suggest aspirin may improve survival in breast cancer patients. However, recent trials reported a lack of protection, though the length of intervention was limited. Among 10,705 stages I-III breast cancer patients in the Nurses' Health Studies (NHS/NHSII), we examined the associations between post-diagnostic aspirin use and long-term breast cancer survival. During up to 34 years of follow-up, regular post-diagnostic aspirin use was associated with a 38% and 28% lower risk of breast cancer-specific and total mortality. Associations were more evident with longer duration of post-diagnostic aspirin use but attenuated with higher stage and older age at diagnosis. Pre-diagnostic long-term aspirin use was associated with the downregulation of tumor proliferation pathways in NHS/NHSII and the aspirin-gene-expression-signature predicted better survival in METABRIC. Our study highlighted the need for trials with longer duration and suggested that aspirin use before diagnosis may alter the tumor-microenvironment towards a less proliferative type.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-06-02T00:28:05.889Z","creation":"2026-05-24T03:07:42.064Z"},"accession":"S-EPMC12216965","cross_references":{"pubmed":["40595613"],"doi":["10.1038/s41523-025-00775-2"]}}